Drug firm Dr Reddy's Laboratories said Monday it has re-launched its generic Zenatane capsules in the US market.
The company has re-launched Zenatane (Isotretinoin Capsules, USP) in the strengths of 10 mg, 20 mg, 30 mg and 40 mg, Dr Reddy's said in a statement.
The product is a generic version of Hoffman LaRoche's Accutane capsules, it added.
The product is being launched with an approved Risk Evaluation and Mitigation Strategy (REMS) Program, Dr Reddy's said.
"We're pleased to bring this important product back to market for the customers and patients who will benefit from access to this medicine and who have had witnessed limited supply and options in the market place," Dr Reddy's North America Generics CEO Marc Kikuchi said.
According to IQVIA Health data, the Zenatane capsules 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD 525 million MAT for the most recent twelve months ending in March 2019.
Shares of Dr Reddy's Laboratories closed at Rs 2,718.90 on BSE, up 1.54 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
